Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2018

View Archived Issues

Cellenkos manufacturing facility is successfully registered as GMP compliant with the FDA

Acesion Pharma cleared to conduct phase I study of AP-30663

Janssen submits MAA to EMA for apalutamide for nonmetastatic CRPC

Phase II trials of BI-409306 in Alzheimer's disease do not meet efficacy endpoints

Novo Nordisk's Ozempic approved in E.U.

Boehringer Ingelheim initiates phase I study of BI-1291583

Aravive studies AVB-S6-500 in healthy volunteers

Lundbeck updates progress of fourth quarter 2017

Tychan initiates phase Ia trial of first-in-class Zika antibody tyzivumab

Puma presents clinical data on neratinib in patients with HER2/3 mutant cancers

Phase III quality of life data reported for turoctocog alfa pegol in hemophilia A

Kissei presents novel CGRP antagonists

Retrophin divulges new pantetheine derivatives for neurodegeneration

New phase I/II trial evaluates lentiviral gene transfer for SCID-X1

Achaogen discloses novel ACC inhibitors for bacterial infections

Novel USP19 inhibitors presented by Almac Discovery

Toray Industries identifies MALT1 inhibitors

Roivant and Poxel sign development and license agreement for imeglimin

Seattle Genetics and Pieris Pharmaceuticals enter immune-oncology collaboration

Scholar Rock's SRK-015 antibody inhibits muscle wasting by binding myostatin precursors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.